Amgen, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1980-01-01
- Employees
- 26.7K
- Market Cap
- $175.6B
- Website
- http://www.amgen.com
Trial Evaluating PCSK9 Antibody in Subjects With LDL Receptor Abnormalities
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2012-05-01
- Last Posted Date
- 2018-11-29
- Lead Sponsor
- Amgen
- Target Recruit Count
- 58
- Registration Number
- NCT01588496
- Locations
- 🇪🇸
Research Site, Madrid, Spain
Transition From Alendronate to Romosozumab (AMG 785)
- First Posted Date
- 2012-05-01
- Last Posted Date
- 2019-03-26
- Lead Sponsor
- Amgen
- Target Recruit Count
- 60
- Registration Number
- NCT01588509
- Locations
- 🇺🇸
Research Site, Seattle, Washington, United States
Efficacy and Safety of Denosumab Compared With Risedronate in Individuals Taking Glucocorticoids
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2012-04-12
- Last Posted Date
- 2018-07-27
- Lead Sponsor
- Amgen
- Target Recruit Count
- 795
- Registration Number
- NCT01575873
- Locations
- 🇪🇸
Research Site, Madrid, Spain
First-in-Human Study to Evaluate AMG 579 in Healthy Subjects and Patients With Stable Schizophrenia
- First Posted Date
- 2012-04-02
- Last Posted Date
- 2012-10-10
- Lead Sponsor
- Amgen
- Target Recruit Count
- 50
- Registration Number
- NCT01568203
- Locations
- 🇺🇸
Research Site, Glendale, California, United States
Open-label Safety and Pharmacokinetic Study of DUEXIS® (Ibuprofen and Famotidine) Tablets in Juvenile Idiopathic Arthritis
Phase 4
Completed
- Conditions
- Interventions
- First Posted Date
- 2012-03-26
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- Amgen
- Target Recruit Count
- 12
- Registration Number
- NCT01563185
- Locations
- 🇺🇸
Dell Children's Medical Center of Central Texas, Austin, Texas, United States
🇺🇸Floating Hospital for Children @ Tufts Medical Center, Boston, Massachusetts, United States
🇺🇸Children's Hospital, New Orleans, Louisiana, United States
A Drug-Drug Interaction Study to Evaluate the Effect of Rifampin on the Pharmacokinetics of Apremilast
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2012-03-23
- Last Posted Date
- 2021-06-09
- Lead Sponsor
- Amgen
- Target Recruit Count
- 21
- Registration Number
- NCT01561963
- Locations
- 🇺🇸
Quintiles, Overland Park, Kansas, United States
A Safety Study of VIMOVO in Adolescents With Juvenile Idiopathic Arthritis (JIA)
Phase 4
Completed
- Conditions
- Interventions
- First Posted Date
- 2012-03-05
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- Amgen
- Target Recruit Count
- 46
- Registration Number
- NCT01544114
- Locations
- 🇺🇸
Research Site, Fairfax, Virginia, United States
Durable Effect of PCSK9 Antibody CompARed wiTh placEbo Study
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2012-01-25
- Last Posted Date
- 2022-07-22
- Lead Sponsor
- Amgen
- Target Recruit Count
- 905
- Registration Number
- NCT01516879
- Locations
- 🇿🇦
Research Site, Bloemfontein, South Africa
Carfilzomib Multiple Myeloma Expanded Access Protocol for Patients With Relapsed and Refractory Disease
- Conditions
- First Posted Date
- 2011-08-05
- Last Posted Date
- 2017-05-02
- Lead Sponsor
- Amgen
- Registration Number
- NCT01410500
Safety Study of AMG 557 in Subjects With Subacute Cutaneous Lupus Erythematosus
- First Posted Date
- 2011-07-08
- Last Posted Date
- 2014-01-10
- Lead Sponsor
- Amgen
- Target Recruit Count
- 1
- Registration Number
- NCT01389895
- Locations
- 🇨🇦
Research Site, Peterborough, Ontario, Canada
© Copyright 2024. All Rights Reserved by MedPath